Real World Psilocybin Outcomes

States

This dashboard shows aggregate, real-world outcomes from licensed psilocybin services at healing centers in Oregon and Colorado, updated in real time as facilitators and centers record sessions. All figures are aggregated across participants; no individual-level data is shown. See Methods & data notes for how this data is collected and what it can and cannot show.

Showing real-world data from January 2025 through September 2026.

Baseline Screening Scores

Wellness (WHO-5) Mean

13.1/ 25

n=3959

Anxiety (GAD-7) Mean

12.2/ 21

n=1297

Depression (PHQ-9) Mean

14.0/ 27

n=1029

Wellness (WHO-5) CHANGE

+2.9

n=1433

13.4 → 16.3

Anxiety (GAD-7) CHANGE

-6.3

n=427

11.9 → 5.6

Depression (PHQ-9) CHANGE

-7.0

n=341

13.6 → 6.6

Wellness (WHO-5): Pre vs Post

n = 1433 paired scores

Baseline
2-Week Post

Anxiety (GAD-7): Pre vs Post

n = 427 paired scores

Baseline
2-Week Post

Depression (PHQ-9): Pre vs Post

n = 341 paired scores

Baseline
2-Week Post

Pre-post comparisons use strict pairing: only participants with both a baseline and two-week post-journey score for the same instrument are included. GAD-7 and PHQ-9 are administered adaptively — they only appear when initial screening scores (GAD-2 ≥ 3 or PHQ-2 ≥ 3) indicate elevated symptoms, so fewer participants have paired scores for these instruments.

Mystical Experiences (MEQ-30)

MEQ-30 Mean Total

99.8/ 150

n=2931

Complete Mystical Experience Rate

66.5%

n=2931

1949 scored >= 90

Adverse Events

Category	Timing	Adverse Events	Sessions Reported	Rate
Behavioral	During Session	401 severe	4966	0.8%
Medical	During Session	523 severe	4969	1.0%
Behavioral	Post Session	10	1778	0.6%
Medical	Post Session	17	1779	1.0%

Severe events are a subset of the adverse event count, not additional to it.